Table of Contents
A single dose of psilocybin appears to reduce reward-seeking behavior in rats for at least 48 hours after administration, and a new study published in the European Journal of Neuroscience now points to a specific cellular mechanism that may explain why: the increased activation of inhibitory neurons wrapped in specialized structures called perineuronal nets. The findings, led by Alberto Del Arco of the University of Mississippi, are preliminary and animal-based, but they offer a plausible biological story for the sustained behavioral shifts observed in prior clinical work on psilocybin and substance use disorders.
Why Reward-Seeking Matters in Addiction
Substance use disorders are characterized in part by what researchers call choice impulsivity, a tendency to favor small, immediate rewards over larger ones that require waiting. This pattern is associated with a higher risk of relapse and difficulty resisting urges. The dorsomedial prefrontal cortex, the brain region central to this study, plays a primary role in processing reward cues and guiding decisions based on their relative value. That region is also densely populated with serotonin receptors, the same receptors that psilocybin binds to when it enters the brain.
Prior clinical trials have shown that a single session of psilocybin-assisted therapy can reduce alcohol and nicotine consumption in humans, and animal models have demonstrated a reduced relapse risk after one dose. What has remained unclear is the biological mechanism behind these durable changes. Del Arco described this as a critical gap: recent evidence supports psilocybin’s utility for substance use disorders, yet how the compound actually alters reward-seeking at the cellular level has not been well understood.
What the Rat Study Found, and How It Was Conducted
To investigate, Del Arco’s team trained adult male Long Evans rats in a delay discounting task. The animals chose between pressing a lever for one sugar pellet delivered after one second, or pressing a different lever for three sugar pellets delivered after either ten or twenty seconds. After approximately twelve days of training, rats showed stable decision patterns. Six rats then received a single injection of psilocybin at one milligram per kilogram of body weight; eight rats received a saline injection as a control.
Testing occurred at 24 and 48 hours after injection, allowing the compound to fully clear the animals’ systems before behavioral assessment. At the 24-hour mark, the two groups performed similarly. By 48 hours, the psilocybin group showed a notable decrease in their preference for the large reward and took significantly longer to press the lever for it. Importantly, this shift did not vary with the length of the wait time, suggesting it was not a change in impulsivity specifically, but a broader reduction in drive toward the larger reward. The rats maintained normal accuracy on forced-choice trials, indicating no impairment in attention or motor function.
The Cellular Mechanism: Parvalbumin Cells and Perineuronal Nets
After the final behavioral tests, the researchers examined brain tissue under microscopy. They found increased activation of parvalbumin interneurons in the deep layers of the dorsomedial prefrontal cortex in the psilocybin group. These fast-firing inhibitory cells suppress the activity of surrounding circuits. Many of them are enclosed in perineuronal nets, a scaffolding of proteins and sugars that form part of the extracellular matrix and regulate how brain cells adapt over time. The study also detected changes in this extracellular matrix 48 hours post-dose, structures the researchers associate with brain plasticity.
The authors propose that psilocybin activates these inhibitory circuits, which in turn dampen the reward-processing signals that drive compulsive seeking behavior. This is a hypothesis generated by a small rodent study, not a confirmed mechanism in humans, and the researchers acknowledge the need for further work to understand the full picture. Still, the cellular specificity of the finding, particular cells, particular structures, in a particular brain region, offers a meaningful direction for future research into how psychedelics may produce lasting change in addiction-related circuits.
The Quiet After the Dose
What strikes us about this research is not the dramatic theater of the psychedelic experience itself, but what appears to happen in its absence. Two days after the compound has left the body, something in the brain's architecture has shifted. The cells that hold things back, the inhibitory interneurons wrapped in their protective nets, are more active. The reach for the large reward has grown quieter.
In the language of practice, this maps onto what many members describe after a ceremony or a guided session: not a sudden transformation, but a gentling of the compulsive pull. The craving does not necessarily vanish, but the urgency loses some of its grip. This study, while animal-based and early, gives that lived report a cellular address.
We hold this finding with appropriate care. Rats pressing levers for sugar pellets are not humans navigating addiction, grief, or the long work of recovery. But the direction of the science continues to point toward the same quiet truth: psilocybin, used with intention and in the right conditions, may help the brain find its own internal steadiness.
If you are in the early stages of your path, or sitting with questions about how this medicine might relate to compulsive patterns in your own life, we welcome you to explore our Grounding resources and to bring your reflections into community. You do not have to understand the neuroscience to feel its resonance.
May love guide the hearts of all beings.
